¼¼°èÀÇ Ç÷°üÁ¾ Ä¡·á ½ÃÀå
Hemangioma Treatment
»óǰÄÚµå : 1792754
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 485 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,215,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,647,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Ç÷°üÁ¾ Ä¡·á ¼¼°è ½ÃÀåÀº 2030³â±îÁö 3¾ï 7,870¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 3¾ï 1,830¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â Ç÷°üÁ¾ Ä¡·á ¼¼°è ½ÃÀåÀº 2024-2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 2.9%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 3¾ï 7,870¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¸ð¼¼Ç÷°üÁ¾Àº CAGR 3.9%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1¾ï 7,340¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÇØ¸é»ó Ç÷°üÁ¾ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 1.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 8,670¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 5.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Ç÷°üÁ¾ Ä¡·á ½ÃÀåÀº 2024³â¿¡ 8,670¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 5.7%·Î 2030³â±îÁö 7,470¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.1%¿Í 2.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Ç÷°üÁ¾ Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÀÇÇÐÀÇ ¹ßÀüÀÌ Ç÷°üÁ¾ Ä¡·á¹ýÀ» ¹Ù²Ü °ÍÀΰ¡?

¿µÀ¯¾Æ¿¡°Ô ¸¹ÀÌ ¹ß»ýÇÏ´Â ¾ç¼º Ç÷°üÁ¾¾çÀÎ Ç÷°üÁ¾Àº ¾à¸®ÇÐ, ¿µ»ó Áø´Ü, ·¹ÀÌÀú ±â¼úÀÇ ¹ß´Þ·Î Ä¡·á Á¢±Ù¹ý¿¡ ÆÐ·¯´ÙÀÓÀÇ º¯È­°¡ ÀϾ°í ÀÖ½À´Ï´Ù. ±âÁ¸¿¡´Â ¸¹Àº Ç÷°üÁ¾ÀÌ ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ÀÚ¿¬ÀûÀ¸·Î ÅðÇàÇÏ´Â °ÍÀ» ±â´Ù¸± ¼ö¹Û¿¡ ¾ø¾úÁö¸¸, ÀνÄÀÇ Áõ°¡, Áø´Ü µµ±¸ÀÇ °³¼±, Á¶±â ¹Ì¿ë ¹× ±â´ÉÀû °³ÀÔ¿¡ ´ëÇÑ ¿ä±¸·Î ÀÎÇØ ÀÇ·á°è´Â º¸´Ù Àû±ØÀûÀÎ Ä¡·á Àü·«À¸·Î ³ª¾Æ°¡°í ÀÖ½À´Ï´Ù. º£Å¸Â÷´ÜÁ¦, ƯÈ÷ ÇÁ·ÎÇÁ¶ó³î·ÑÀÇ µµÀÔÀº 1Â÷ ¼±Åà ¿ä¹ý¿¡ Çõ¸íÀ» °¡Á®¿ÔÀ¸¸ç, ÃÖ¼ÒÇÑÀÇ ºÎÀÛ¿ëÀ¸·Î Áõ½Ä¼º ¼Ò¾Æ Ç÷°üÁ¾ÀÇ º´º¯ Å©±â¿Í »öÁ¶¸¦ ±ØÀûÀ¸·Î °¨¼Ò½ÃÄ×½À´Ï´Ù. ÀÌ·¯ÇÑ ÀüȯÀ¸·Î °ú°Å ³»°úÀû °ü¸®ÀÇ ÇÙ½ÉÀ̾ú´ø Àü½Å ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵忡 ´ëÇÑ ÀÇÁ¸µµ°¡ ÇöÀúÈ÷ ³·¾ÆÁ³½À´Ï´Ù. ÀÌ¿Í ÇÔ²² Ƽ¸ô·Ñ ¸»·¹Àλ꿰À» ÀÌ¿ëÇÑ ±¹¼Ò Ä¡·á´Â Ç¥À缺 Ç÷°üÁ¾, ƯÈ÷ Àü½Å Ä¡·á°¡ Á¤´çÈ­µÇÁö ¾Ê´Â °æ¿ì¿¡ Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù. Áø´Ü Ãø¸é¿¡¼­´Â °íÁÖÆÄ ÃÊÀ½ÆÄ, µµÇ÷¯ °Ë»ç, MRI µî ÷´Ü ¿µ»ó Áø´ÜÀ» ÅëÇØ ÀÓ»óÀÇ´Â Ç÷°üÁ¾°ú ´Ù¸¥ Ç÷°ü ÀÌ»óÀ» º¸´Ù Á¤È®ÇÏ°Ô °¨º°ÇÒ ¼ö ÀÖ°Ô µÇ¾î Àû½Ã¿¡ ÀûÀýÇÑ Ä¡·á¸¦ ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ÆÞ½º »ö¼Ò ·¹ÀÌÀú¿Í Nd:YAG ·¹ÀÌÀú¸¦ Æ÷ÇÔÇÑ ·¹ÀÌÀú Ä¡·á´Â ƯÈ÷ ¾ó±¼À̳ª ¸ñ°ú °°ÀÌ ¹Ì¿ëÀûÀ¸·Î ¹Î°¨ÇÑ ºÎÀ§¿¡ ³²¾ÆÀÖ´Â ¹ßÀûÀ̳ª Ç¥À缺 º´º¯¿¡ ´ëÇÑ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº Ä¡·áÀÇ ÆÐ·¯´ÙÀÓÀ» ¼öµ¿ÀûÀÎ "ÁöÄѺ¸±â" Á¢±Ù¹ý¿¡¼­ º¸´Ù Àû±ØÀûÀÌ°í °á°ú Áß½ÉÀÇ Àü·«À¸·Î ¹Ù²Ù°í ÀÖ½À´Ï´Ù. Ç÷°üÁ¾ÀÇ Áõ½Ä°ú ÅðÇà¿¡ °ü¿©ÇÏ´Â ºÐÀÚ ¸¶Ä¿¿Í À¯ÀüÀû °æ·Î°¡ ¹àÇôÁö¸é¼­ »ý¹°ÇÐÀû Ä¡·á¿Í À¯ÀüÀÚ Ç¥Àû Ä¡·áÀÇ »õ·Î¿î ±æÀÌ ¸ð»öµÇ°í ÀÖÀ¸¸ç, ÇâÈÄ ¸ÂÃãÇü Ä¡·áÀÇ ´ë¾ÈÀÌ µÉ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

¿À´Ã³¯ ÀÓ»ó¿¡¼­ ¼Ò¾Æ Ç÷°üÁ¾°ú ¼ºÀÎ Ç÷°üÁ¾Àº ¾î¶»°Ô ´Ù¸£°Ô Ä¡·áµÇ°í Àִ°¡?

¼Ò¾Æ Ç÷°üÁ¾°ú ¼ºÀÎ Ç÷°üÁ¾À» ±¸ºÐÇÏ´Â °ÍÀº Ä¡·á °èȹÀ» Á¶Á¤ÇÏ´Â µ¥ Áß¿äÇÑ ¿ä¼ÒÀÔ´Ï´Ù. ¼Ò¾Æ Ç÷°üÁ¾, ƯÈ÷ À¯¾Æ±â¿¡ ¹ß°ßµÈ Ç÷°üÁ¾Àº Á¾Á¾ ±Þ¼ÓÇÑ Áõ½Ä±â¸¦ °ÅÃÄ ¼­¼­È÷ ÅðÇàÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ±×·¯³ª ½Ã·Â, È£Èí, ¼·½ÄÀ» ¹æÇØÇϰųª Áß¿äÇÑ ºÎÀ§¿¡ ¿µ±¸ÀûÀÎ ÈäÅ͸¦ À¯¹ßÇÒ ¼ö Àֱ⠶§¹®¿¡ Á¶±â °³ÀÔÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ ¶§¹®¿¡ ½Å»ý¾Æ ¹× ¼Ò¾Æ ÇǺΰú¿¡¼­ ÇÁ·ÎÇÁ¶ó³î·Ñ ÇÁ·ÎÅäÄÝÀÌ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, ÇǺΰú ÀÇ»ç, ¼Ò¾Æ°ú ÀÇ»ç, ¶§·Î´Â ¼Ò¾Æ ¿Ü°ú Àǻ縦 Æ÷ÇÔÇÑ ´ÙÇÐÁ¦Àû Ä¡·á°¡ ÃÖÀûÀÇ °á°ú¸¦ º¸ÀåÇÕ´Ï´Ù. ÀÌ¿Í ´Þ¸® ¼ºÀÎ Ç÷°üÁ¾Àº °£, ôÃß, ÇǺο¡ ¹ß»ýÇÏ´Â °æ¿ì°¡ ¸¹¾Æ ÀÓ»óÀûÀ¸·Î ¶Ñ·ÇÇÑ ¾î·Á¿òÀÌ Á¸ÀçÇÕ´Ï´Ù. º¸ÅëÀº ¹«Áõ»óÀÌÁö¸¸, Å« °£Ç÷°üÁ¾À̳ª ôÃßÇ÷°üÁ¾Àº ÅëÁõ, ÃâÇ÷, ÀÎÁ¢ ±¸Á¶¹° ¾Ð¹Ú µîÀÇ ÇÕº´ÁõÀ» À¯¹ßÇÒ ¼ö ÀÖÀ¸¸ç, »öÀü¼ú, °íÁÖÆÄ ¼ÒÀÛ¼ú, ¼ö¼úÀû ÀýÁ¦¼úÀÌ »ç¿ëµÇ±âµµ ÇÕ´Ï´Ù. ÀÎÅͺ¥¼Ç ¿µ»óÀÇÇÐ(interventional radiology)ÀÇ ¹ßÀüÀ¸·Î ¼ºÀÎ Ä¡·á ÇöÀå¿¡¼­ ÃÖ¼Òħ½ÀÀû Á¢±ÙÀÌ È°¹ßÇØÁö¸é¼­ ȸº¹ ½Ã°£°ú ½Ã¼úÀÇ À§ÇèÀÌ Å©°Ô ÁÙ¾ú½À´Ï´Ù. ¹Ì¿ëÇǺΰú¿¡¼­´Â ÇǺÎÇ÷°üÁ¾ÀÌ Áö¼ÓµÇ°Å³ª »õ·Î ¹ß»ýÇÑ °í·ÉÀÇ È¯ÀÚµéÀÌ ½É¹ÌÀûÀÎ ¹®Á¦·Î Ä¡·á¸¦ ¿øÇÏ´Â °æ¿ì°¡ ¸¹¾ÆÁö¸é¼­ ·¹ÀÌÀú³ª °æÈ­¿ä¹ý »ç¿ëÀ» ±ÇÀ¯Çϰí ÀÖ½À´Ï´Ù. ¼Ò¾Æ ȯÀÚ¿Í ¼ºÀΠȯÀÚÀÇ Ç÷°ü ±¸Á¶, µ¿¹Ý Áúȯ ¹× Ä¡·á ³»¼ºÀÇ Â÷ÀÌ´Â ¿¬·Éº° ÇÁ·ÎÅäÄÝ °³¹ß¿¡ ´õ ¸¹Àº ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. »õ·Î¿î °¡À̵å¶óÀÎÀº °üÂû, ¾à¹° Ä¡·á, ¼ö¼úÀû ÁßÀç Áß ¾î´À °ÍÀÌ °¡Àå ÀûÀýÇÑÁö °áÁ¤Çϱâ À§ÇØ È¯ÀÚ ¸ÂÃãÇü Æò°¡ µµ±¸¿Í À§Çèµµ Æò°¡ Á¡¼ö¸¦ °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾ç¸éÀûÀÎ ÀÓ»óÀû Á¢±ÙÀº °¢ ¿¬·É´ë¿¡¼­ Ç÷°üÁ¾ Ä¡·áÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» ÃÖÀûÈ­ÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù.

Ç÷°üÁ¾ÀÇ ¹Ì¿ëÀû, ½É¸®Àû ¿µÇâÀÌ Á¶±â °³ÀÔ Ãß¼¼¸¦ ÃËÁøÇϴ°¡?

½É¹Ì¼º, QOL, ½É¸®Àû Çູ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁø °ÍÀº Ç÷°üÁ¾ Ä¡·áÀÇ »óȲÀ» Çü¼ºÇÏ´Â °­·ÂÇÑ ÈûÀÌ µÇ°í ÀÖ½À´Ï´Ù. °ú°Å¿¡´Â Ç÷°üÁ¾Àº ´ëºÎºÐ ÀÚ¿¬ÀûÀ¸·Î ÅðÇàÇÑ´Ù´Â »ý°¢ ¶§¹®¿¡ ¹Ì¿ëÀûÀ¸·Î Å« ¿µÇâÀ» ¹ÌÄ¡´Â °æ¿ì¶óµµ Ä¡·á°¡ ´Ê¾îÁö°Å³ª ÃÖ¼ÒÈ­ÇÏ´Â °æ¿ì°¡ ¸¹¾Ò½À´Ï´Ù. ±×·¯³ª ÃÖ±Ù ¿¬±¸¿¡ µû¸£¸é ´«¿¡ º¸ÀÌ´Â Ç÷°üÁ¾ÀÇ Áö¼ÓÀûÀÎ ½É¸®»çȸÀû ¿µÇâ, ƯÈ÷ »çȸÀû ³«ÀÎ, µûµ¹¸² ¶Ç´Â ÀÚÁ¸°¨ ¹®Á¦¸¦ °ÞÀ» ¼ö ÀÖ´Â Çзɱ⠾Ƶ¿¿¡°Ô ¹ÌÄ¡´Â ¿µÇâÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù. ÀÌ ¶§¹®¿¡ ƯÈ÷ ¾ó±¼, µÎÇÇ ¶Ç´Â ³ëÃâ ºÎÀ§ÀÇ º´º¯¿¡ ´ëÇÑ Á¶±â °³ÀÔ¿¡ ´ëÇÑ ºÎ¸ðµéÀÇ ¿ä±¸°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¼Ò¾Æ°ú Àǻ糪 ÇǺΰú ÀÇ»çµéÀº ½É¸®ÇÐÀû Æò°¡¿Í »îÀÇ Áú ôµµ¸¦ Ä¡·á °èȹ¿¡ Æ÷ÇÔ½ÃÄÑ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼Ò¼È ¹Ìµð¾î¿Í µðÁöÅÐ Çコ Ç÷§ÆûÀº °£º´ÀÎÀÇ ÀνÄÀ» ³ô¿© ´õ »¡¸® ÁøÂûÀ» ¹Þ°í ´õ »¡¸® Ä¡·á¸¦ ½ÃÀÛÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ¹Ì¿ë ÇǺΰú¿¡¼­´Â ¾È¸é Ç÷°üÁ¾À̳ª ÀÜÁ¸ Ç÷°üÁ¾À» °¡Áø ¼ºÀÎÀÌ ·¹ÀÌÀú¸¦ ÀÌ¿ëÇÑ Ä¡·á³ª ¼ö¼úÀû ±³Á¤À» ¼±ÅÃÇÏ´Â °æ¿ì°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÃÖ¼Òħ½ÀÀû ´ë¾È¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ß´Â ¶ÇÇÑ Ä¡·á °úÁ¤À» ¸ð´ÏÅ͸µÇÏ°í °³ÀÔÀ» Á¤È®ÇÏ°Ô °èȹÇϱâ À§ÇØ ´õ¸ð½ºÄÚÇÇ¿Í 3D ¾È¸é ½ºÄµÀÇ È°¿ëÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. Ç÷°üÁ¾ Ä¡·áÀÇ º¸Çè Àû¿ëÀº ÀÌÀü¿¡´Â ¸¹Àº ±¹°¡¿¡¼­ ¼±ÅÃÀû Ä¡·á·Î ¿©°ÜÁ³Áö¸¸, ±× ±â´ÉÀû, ½É¸®Àû ¿µÇâ, ƯÈ÷ Á¶±â Ä¡·á°¡ Àå±âÀûÀÎ ÇÕº´ÁõÀ» ¿¹¹æÇÒ ¼ö ÀÖ´Ù´Â Á¡À» ÀνÄÇϸ鼭 Á¡Â÷ ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. »ó´ã, Áö¿ø ±×·ì, Á¾ÇÕÀûÀÎ Á¤½Å°Ç°­ ¼Ò°³¸¦ Æ÷ÇÔÇÑ ÀüÀÎÀû Ä¡·á¿¡ ÁßÁ¡À» µÎ´Â °ÍÀº Ç÷°üÁ¾ Ä¡·á¸¦ ÀÇÇÐÀûÀ¸·Î ÇÊ¿äÇÑ °Í»Ó¸¸ ¾Æ´Ï¶ó Àü¹ÝÀûÀÎ À£ºùÀÇ ÇʼöÀûÀÎ ºÎºÐÀ¸·Î °£ÁÖÇÏ´Â ´õ ±¤¹üÀ§ÇÑ ¿òÁ÷ÀÓÀ» ¹Ý¿µÇÕ´Ï´Ù. ±× °á°ú, ½É¹ÌÀû °á°ú¿Í ȯÀÚ ¸¸Á·µµ´Â Ä¡·áÀÇ È¿°ú¸¦ Æò°¡ÇÏ´Â µ¥ ÀÖ¾î ÀÓ»óÀû ¼º°ø ÁöÇ¥¸¸Å­À̳ª Áß¿äÇÑ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

Àü ¼¼°è Ç÷°üÁ¾ Ä¡·áÁ¦ÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?

Ç÷°üÁ¾ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ÀÇ·á ±â¼ú Çõ½Å, Àα¸Åë°èÇÐÀû º¯È­, ÀÓ»ó Áø·á µ¿Çâ, ȯÀÚ Çൿ¿¡ »Ñ¸®¸¦ µÐ ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °¡Àå °­·ÂÇÑ ÃËÁø¿äÀÎ Áß Çϳª´Â ƯÈ÷ ¹Ì¼÷¾Æ ¹× ÀúüÁ߾ƿ¡¼­ ¿µ¾Æ Ç÷°üÁ¾ÀÇ ¹ß»ý·üÀÌ Áõ°¡ÇÏ¿© Á¶±â Áø´Ü ¹× Ä¡·áÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¾à¹° Ä¡·áÀÇ ¹ßÀü, ƯÈ÷ °æ±¸¿ë ¹× ±¹¼Ò¿ë º£Å¸ Â÷´ÜÁ¦ÀÇ ¼º°øÀº Ä¡·á ¿É¼Ç°ú Á¢±Ù¼ºÀ» ȹ±âÀûÀ¸·Î È®´ëÇÏ¿© ÀÇ»çÀÇ µµÀÔ°ú ºÎ¸ðÀÇ ¼ö¿ä¸¦ ¸ðµÎ ÃËÁøÇß½À´Ï´Ù. ¿µ»ó Áø´Ü ¹× ·¹ÀÌÀú ÀåºñÀÇ ±â¼ú ¹ßÀüÀº ´õ ºü¸£°í, ´õ ¾ÈÀüÇϰí, ´õ È¿°úÀûÀÎ Ä¡·á¸¦ °¡´ÉÇÏ°Ô Çϰí, Ä¡·á Ƚ¼ö¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. Àα¸Åë°èÇÐÀû °üÁ¡¿¡¼­ º¼ ¶§, ¼¼°è Àα¸ÀÇ Áõ°¡¿Í ½Å»ý¾Æ Ä¡·áÀÇ °³¼±À¸·Î Ç÷°üÁ¾¿¡ Ãë¾àÇÑ ¹Ì¼÷¾ÆÀÇ »ýÁ¸À²ÀÌ Çâ»óµÇ¾î ȯÀÚ ±â¹ÝÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇǺΰú¿Í ¹Ì¿ë¼¾ÅÍÀÇ ±ÞÁõ°ú ÇÔ²² ¿¬·É´ë¸¦ ºÒ¹®ÇÏ°í ³ô¾ÆÁø ¹ÌÀǽÄÀÌ ÀÜÁ¸ Ç÷°üÁ¾°ú ¼ºÀÎ ¹ßº´ Ç÷°üÁ¾ÀÇ Ä¡·áÀ²À» ³ôÀ̰í ÀÖ½À´Ï´Ù. ½ÅÈï ½ÃÀåÀÇ ÀÇ·á ½Ã½ºÅÛÀº ¼Ò¾Æ ÇǺΰú ¹× ÁßÀçÀû ¹æ»ç¼± ¼­ºñ½º¸¦ È®´ëÇÏ¿© Ç÷°üÁ¾ Ä¡·á¿¡ ´ëÇÑ Æø³ÐÀº Á¢±ÙÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. º¸Çè Àû¿ë È®´ë¿Í Á¤ºÎÀÇ ÀÎ½Ä °³¼± ÇÁ·Î±×·¥µµ Á¶±â ÀÇ·Ú¿Í Àû±ØÀûÀÎ Ä¡·á¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á Á¦°øÀÚ Ãø¸é¿¡¼­´Â ´ÙÇÐÁ¦Àû Ä¡·á ¸ðµ¨°ú Àü¹® ¼¾Å͸¦ ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÊ¿¡ µû¶ó Ä¡·á È¿°ú°¡ Çâ»óµÇ°í ÀÓ»ó ¿ª·®ÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, µðÁöÅÐ °Ç°­¿¡ ´ëÇÑ ÀνÄ, ¿Â¶óÀÎ °æÇè´ã, ¼º°ø »ç·ÊÀÇ °¡½ÃÈ­·Î ÀÎÇØ ȯÀÚµéÀÇ ÇൿÀº Áõ°Å¿¡ ±â¹ÝÇÑ Á¶±â °³ÀÔÀ¸·Î ÀüȯµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÇ À¶ÇÕÀ¸·Î Ç÷°üÁ¾ Ä¡·á ½ÃÀåÀº Àü ¼¼°èÀûÀ¸·Î °­·ÂÇÑ ¼ºÀå ±Ëµµ¿¡ ÁøÀÔÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(¸ð¼¼Ç÷°üÁ¾, ÇØ¸é»ó Ç÷°üÁ¾, º¹ÇÕ Ç÷°üÁ¾, ¼Ò¿± ¸ð¼¼Ç÷°üÁ¾), Áø´Ü(ÃÊÀ½ÆÄ Áø´Ü, MRI Áø´Ü, CT ½ºÄµ Áø´Ü, ±âŸ Áø´Ü), Ä¡·á À¯Çü(ÀÇ·á ¿ä¹ý Ä¡·á, ·¹ÀÌÀú ¿ä¹ý Ä¡·á, ¼ö¼ú Ä¡·á, ¥âÂ÷´ÜÁ¦ Ä¡·á, ¾à¹° Ä¡·á, ±âŸ Ä¡·á À¯Çü), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø¡¤Áø·á¼Ò ÃÖÁ¾»ç¿ëÀÚ, Áø´Ü ¼¾ÅÍ ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Hemangioma Treatment Market to Reach US$378.7 Million by 2030

The global market for Hemangioma Treatment estimated at US$318.3 Million in the year 2024, is expected to reach US$378.7 Million by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Capillary Hemangioma, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$173.4 Million by the end of the analysis period. Growth in the Cavernous Hemangioma segment is estimated at 1.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$86.7 Million While China is Forecast to Grow at 5.7% CAGR

The Hemangioma Treatment market in the U.S. is estimated at US$86.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$74.7 Million by the year 2030 trailing a CAGR of 5.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Hemangioma Treatment Market - Key Trends & Drivers Summarized

Is Advancing Medical Science Changing the Way We Treat Hemangiomas?

Hemangiomas-benign vascular tumors often seen in infants and young children-are undergoing a paradigm shift in treatment approaches thanks to developments in pharmacology, imaging, and laser technology. Traditionally, many hemangiomas were left to involute naturally over time; however, increasing awareness, improved diagnostic tools, and demand for early aesthetic and functional intervention have driven the medical community toward more proactive treatment strategies. The introduction of beta-blockers, particularly propranolol, has revolutionized first-line therapy, dramatically reducing lesion size and color in proliferating infantile hemangiomas with minimal side effects. This shift has significantly decreased reliance on systemic corticosteroids, once the cornerstone of medical management. In parallel, topical treatments using timolol maleate are gaining popularity for superficial hemangiomas, especially when systemic therapy is not warranted. On the diagnostic front, advanced imaging modalities such as high-frequency ultrasound, Doppler studies, and MRI allow clinicians to differentiate between hemangiomas and other vascular anomalies more accurately, enabling targeted and timely therapy. Moreover, the use of laser therapies, including pulsed dye and Nd:YAG lasers, is increasing for residual redness and superficial lesions, especially in cosmetically sensitive areas like the face and neck. These innovations are transforming the treatment paradigm from a passive “wait-and-see” approach to a more aggressive, outcome-oriented strategy. As research uncovers molecular markers and genetic pathways involved in hemangioma proliferation and involution, new avenues for biologic and gene-targeted therapies are also being explored, offering hope for personalized treatment options in the future.

Are Pediatric and Adult Hemangiomas Being Managed Differently in Today’s Clinical Practice?

The distinction between infantile and adult hemangiomas has become a critical factor in tailoring treatment plans, as clinicians increasingly recognize that one-size-fits-all solutions are no longer acceptable. Pediatric hemangiomas, especially those identified in infancy, often undergo a rapid proliferation phase followed by gradual involution. However, their potential to interfere with vision, breathing, feeding, or cause permanent disfigurement in vital areas necessitates early intervention. This has led to widespread adoption of propranolol protocols in neonatology and pediatric dermatology settings, where multidisciplinary care involving dermatologists, pediatricians, and sometimes pediatric surgeons ensures optimal outcomes. In contrast, adult hemangiomas-most often found in the liver, spine, or skin-present distinct clinical challenges. Though usually asymptomatic, large hepatic or vertebral hemangiomas may cause complications like pain, bleeding, or compression of adjacent structures, leading to the use of embolization, radiofrequency ablation, or even surgical resection. The evolution of interventional radiology has allowed minimally invasive approaches to flourish in adult treatment settings, significantly reducing recovery time and procedural risk. In cosmetic dermatology, older patients with persistent or newly developing cutaneous hemangiomas are increasingly seeking treatment due to aesthetic concerns, prompting the use of laser and sclerotherapy techniques. Differences in vascular structure, comorbidities, and treatment tolerance between pediatric and adult patients have further influenced the development of age-specific protocols. Emerging guidelines now emphasize customized assessment tools and risk stratification scores to decide whether observation, pharmacologic therapy, or procedural intervention is most appropriate. This dual-pronged clinical approach is helping optimize safety and efficacy in hemangioma treatment across age groups.

Is the Cosmetic and Psychological Impact of Hemangiomas Driving Early Intervention Trends?

The rising emphasis on aesthetics, quality of life, and psychological well-being has become a powerful force shaping the hemangioma treatment landscape. In the past, the assumption that most hemangiomas would regress naturally led to delayed or minimal treatment, even in cases with significant cosmetic impact. However, more recent studies underscore the lasting psychosocial consequences of visible hemangiomas, particularly in school-aged children who may experience social stigma, bullying, or self-esteem issues. This has led to a sharp increase in parental demand for early intervention, especially for lesions on the face, scalp, or exposed areas. Pediatricians and dermatologists are responding by integrating psychological assessments and quality-of-life measures into treatment planning. Furthermore, social media and digital health platforms are increasing awareness among caregivers, leading to earlier consultation and faster initiation of therapy. In cosmetic dermatology, adults with facial or residual hemangiomas are increasingly opting for laser-based or surgical corrective procedures, further expanding demand for minimally invasive options. The field has also seen growing use of dermoscopy and 3D facial scanning to monitor treatment progress and plan interventions with precision. Insurance coverage for hemangioma treatment, previously considered elective in many countries, is gradually evolving in recognition of its functional and psychological impact, particularly when early treatment can prevent long-term complications. The emphasis on holistic care-including counseling, support groups, and integrated mental health referrals-reflects a broader movement toward viewing hemangioma treatment as not only a medical necessity but also an essential part of comprehensive well-being. As a result, aesthetic outcomes and patient satisfaction are becoming as important as clinical success metrics in evaluating treatment efficacy.

What Are the Major Drivers Fueling the Global Growth in Hemangioma Treatment?

The growth in the hemangioma treatment market is driven by several factors rooted in medical innovation, demographic shifts, clinical practice trends, and patient behavior. One of the strongest drivers is the increasing incidence of infantile hemangiomas, particularly among premature and low birth weight infants, which has led to a greater need for early diagnosis and treatment. Advances in pharmacological therapies-especially the success of oral and topical beta-blockers-have dramatically expanded treatment options and accessibility, driving both physician adoption and parental demand. Technological advancements in diagnostic imaging and laser devices are facilitating earlier, safer, and more effective interventions, further boosting procedural volumes. From a demographic perspective, the growing global population and improved neonatal care are resulting in higher survival rates among preterm infants, who are more susceptible to hemangiomas, thereby expanding the patient base. Additionally, a rise in aesthetic consciousness across age groups is increasing treatment uptake for residual or adult-onset hemangiomas, supported by the proliferation of dermatology clinics and cosmetic centers. Health systems in emerging markets are expanding pediatric dermatology and interventional radiology services, enabling broader access to hemangioma care. Increasing insurance coverage and government awareness programs are also contributing to early referrals and proactive care. On the provider side, the availability of multidisciplinary care models and specialty centers is improving treatment efficacy and expanding clinical capacity. Lastly, patient behavior is shifting toward early, evidence-based intervention, fueled by digital health awareness, online testimonials, and the visibility of successful outcomes. These converging factors are establishing a robust growth trajectory for the hemangioma treatment market worldwide.

SCOPE OF STUDY:

The report analyzes the Hemangioma Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Capillary Hemangioma, Cavernous Hemangioma, Compound Hemangioma, Lobular Capillary Hemangioma); Diagnosis (Ultrasound Diagnosis, MRI Diagnosis, CT Scan Diagnosis, Other Diagnosis); Treatment Type (Medical Therapy Treatment, Laser Therapy Treatment, Surgery Treatment, Beta Blocker Treatment, Medicines Treatment, Other Treatment Types); End-Use (Hospitals & Clinics End-Use, Diagnostic Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â